Intersect ENT Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 433

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.2B

Intersect ENT General Information

Description

Developer of integrated medical technologies designed to improve care for those suffering from chronic rhinosinusitis. The company offers mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses, enabling patients to experience better health outcomes and enhanced quality of life.

Contact Information

Formerly Known As
Sinexus, Sinexus Inc
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1555 Adams Drive
  • Menlo Park, CA 94025
  • United States
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Acquirer
Medtronic
Corporate Office
  • 1555 Adams Drive
  • Menlo Park, CA 94025
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intersect ENT Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Merger/Acquisition 13-May-2022 $1.2B Completed Generating Revenue
15. Merger/Acquisition 08-Jul-2020 Cancelled Generating Revenue
14. Secondary Transaction - Open Market Completed Generating Revenue
13. Secondary Transaction - Open Market 31-Jan-2018 Completed Generating Revenue
12. PIPE 31-Aug-2016 Completed Generating Revenue
11. 2PO 03-Jun-2016 Completed Generating Revenue
10. Secondary Transaction - Open Market 31-Jan-2016 Completed Generating Revenue
9. PIPE 05-Nov-2015 Completed Generating Revenue
8. Secondary Transaction - Open Market 31-Mar-2015 $146M Completed Generating Revenue
7. IPO 24-Jul-2014 $55M $146M Completed Generating Revenue
To view Intersect ENT’s complete valuation and funding history, request access »

Intersect ENT Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of integrated medical technologies designed to improve care for those suffering from chronic rhinosinusitis. T
Therapeutic Devices
Menlo Park, CA
433 As of 2021

Shelton, CT
 

Braintree, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Intersect ENT Competitors (11)

One of Intersect ENT’s 11 competitors is Spine Wave, a Venture Capital-Backed company based in Shelton, CT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Spine Wave Venture Capital-Backed Shelton, CT
NEUROMARK Venture Capital-Backed Braintree, MA
Biotronik Corporate Backed or Acquired Berlin, Germany
Boston Scientific Corporation Marlborough, MA
CardioFocus Venture Capital-Backed Marlborough, MA
You’re viewing 5 of 11 competitors. Get the full list »

Intersect ENT Patents

Intersect ENT Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250295507-A1 Catheter for delivering a nasal stent Pending 22-Mar-2024
WO-2025199445-A1 Sinus and nasal stent Pending 22-Mar-2024
AU-2020336462-A1 Submucosal bioresorbable drug eluting platform Inactive 30-Aug-2019
CA-3152762-A1 Submucosal bioresorbable drug eluting platform Pending 30-Aug-2019
EP-4021343-A1 Submucosal bioresorbable drug eluting platform Pending 30-Aug-2019 A61M37/0069
To view Intersect ENT’s complete patent history, request access »

Intersect ENT Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intersect ENT Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aisling Capital Venture Capital Minority
Cheyenne Partners Venture Capital Minority
Duff Ackerman & Goodrich PE/Buyout Minority
Foresite Capital Growth/Expansion Minority
Harmony Partners Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Intersect ENT Acquisitions (1)

Intersect ENT’s most recent deal was a Merger/Acquisition with Fiagon for . The deal was made on 02-Oct-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Fiagon 02-Oct-2020 Merger/Acquisition Surgical Devices
To view Intersect ENT’s complete acquisitions history, request access »

Intersect ENT ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

15.53 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view Intersect ENT’s complete esg history, request access »

Intersect ENT FAQs

  • When was Intersect ENT founded?

    Intersect ENT was founded in 2003.

  • Where is Intersect ENT headquartered?

    Intersect ENT is headquartered in Menlo Park, CA.

  • What is the size of Intersect ENT?

    Intersect ENT has 433 total employees.

  • What industry is Intersect ENT in?

    Intersect ENT’s primary industry is Therapeutic Devices.

  • Is Intersect ENT a private or public company?

    Intersect ENT is a Private company.

  • What is the current valuation of Intersect ENT?

    The current valuation of Intersect ENT is .

  • What is Intersect ENT’s current revenue?

    The current revenue for Intersect ENT is .

  • How much funding has Intersect ENT raised over time?

    Intersect ENT has raised $151M.

  • Who are Intersect ENT’s investors?

    Aisling Capital, Cheyenne Partners, Duff Ackerman & Goodrich, Foresite Capital, and Harmony Partners are 5 of 12 investors who have invested in Intersect ENT.

  • Who are Intersect ENT’s competitors?

    Spine Wave, NEUROMARK, Biotronik, Boston Scientific, and CardioFocus are some of the 11 competitors of Intersect ENT.

  • When was Intersect ENT acquired?

    Intersect ENT was acquired on 13-May-2022.

  • Who acquired Intersect ENT?

    Intersect ENT was acquired by Medtronic.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process